253 related articles for article (PubMed ID: 25030036)
1. Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.
Gebauer N; Gebauer J; Hardel TT; Bernard V; Biersack H; Lehnert H; Rades D; Feller AC; Thorns C
Leuk Lymphoma; 2015 Apr; 56(4):1100-6. PubMed ID: 25030036
[TBL] [Abstract][Full Text] [Related]
2. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
[TBL] [Abstract][Full Text] [Related]
3. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
4. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
Reimann M; Schrezenmeier J; Richter-Pechanska P; Dolnik A; Hick TP; Schleich K; Cai X; Fan DNY; Lohneis P; Maßwig S; Denker S; Busse A; Knittel G; Flümann R; Childs D; Childs L; Gätjens-Sanchez AM; Bullinger L; Rosenwald A; Reinhardt HC; Schmitt CA
Blood; 2021 May; 137(20):2785-2799. PubMed ID: 33232972
[TBL] [Abstract][Full Text] [Related]
5. VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.
Nichele I; Zamò A; Bertolaso A; Bifari F; Tinelli M; Franchini M; Stradoni R; Aprili F; Pizzolo G; Krampera M
PLoS One; 2012; 7(12):e52811. PubMed ID: 23285191
[TBL] [Abstract][Full Text] [Related]
6. Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.
Gebauer N; Künstner A; Ketzer J; Witte HM; Rausch T; Benes V; Zimmermann J; Gebauer J; Merz H; Bernard V; Harder L; Ratjen K; Gesk S; Peter W; Busch Y; Trojok P; von Bubnoff N; Biersack H; Busch H; Feller AC
Blood Cancer J; 2021 May; 11(5):102. PubMed ID: 34039950
[TBL] [Abstract][Full Text] [Related]
7. A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma.
Dong G; Chanudet E; Zeng N; Appert A; Chen YW; Au WY; Hamoudi RA; Watkins AJ; Ye H; Liu H; Gao Z; Chuang SS; Srivastava G; Du MQ
Clin Cancer Res; 2011 Mar; 17(6):1440-51. PubMed ID: 21266526
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
9.
Vermaat JS; Somers SF; de Wreede LC; Kraan W; de Groen RAL; Schrader AMR; Kerver ED; Scheepstra CG; Berenschot H; Deenik W; Wegman J; Broers R; de Boer JD; Nijland M; van Wezel T; Veelken H; Spaargaren M; Cleven AH; Kersten MJ; Pals ST
Haematologica; 2020; 105(2):424-434. PubMed ID: 31123031
[TBL] [Abstract][Full Text] [Related]
10. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
11. Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.
Bu R; Bavi P; Abubaker J; Jehan Z; Al-Haqawi W; Ajarim D; Al-Dayel F; Uddin S; Al-Kuraya KS
Leuk Lymphoma; 2012 Oct; 53(10):1971-7. PubMed ID: 22397314
[TBL] [Abstract][Full Text] [Related]
12. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
Yamada S; Ishida Y; Matsuno A; Yamazaki K
Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.
Ozsan N; Cagirgan S; Saydam G; Gunes A; Hekimgil M
Pathol Res Pract; 2013 Aug; 209(8):471-8. PubMed ID: 23726928
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of NF-κB deregulation in lymphoid malignancies.
Krappmann D; Vincendeau M
Semin Cancer Biol; 2016 Aug; 39():3-14. PubMed ID: 27262792
[TBL] [Abstract][Full Text] [Related]
15. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
Lenz G; Davis RE; Ngo VN; Lam L; George TC; Wright GW; Dave SS; Zhao H; Xu W; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Chan WC; Staudt LM
Science; 2008 Mar; 319(5870):1676-9. PubMed ID: 18323416
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: Is It Different between Over and Under 50 Years of Age?
Monabati A; Vahedi A; Safaei A; Noori S; Mokhtari M; Vahedi L; Zamani M
Asian Pac J Cancer Prev; 2016; 17(4):2285-9. PubMed ID: 27221931
[TBL] [Abstract][Full Text] [Related]
18. TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
Cho J; Kim E; Yoon SE; Kim SJ; Kim WS
Cancer; 2023 May; 129(10):1502-1512. PubMed ID: 36812290
[TBL] [Abstract][Full Text] [Related]
19. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
[TBL] [Abstract][Full Text] [Related]
20. A distinctive subgroup of oral EBV+ B-cell neoplasm with polymorphous features is potentially identical to EBV+ mucocutaneous ulcer.
Ohata Y; Tatsuzawa A; Ohyama Y; Ichikawa A; Mochizuki Y; Ishibashi S; Itakura Y; Sakurai U; Sakamoto K; Ikeda T; Kitagawa M; Yamamoto K
Hum Pathol; 2017 Nov; 69():129-139. PubMed ID: 28993276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
